- HLS Therapeutics has entered into an agreement with Bayer to commercialize Verquvo (vericiguat) in Canada, marking HLS’s entry into heart failure and strengthening its cardiovascular portfolio.
- Verquvo is an oral, once-daily treatment for adults with symptomatic chronic heart failure and reduced ejection fraction who have stabilized after a recent hospitalization or IV diuretic treatment.
- Already authorized and available in Canada since April 2023, Verquvo is supported by the Phase III VICTORIA trial and has public and private reimbursement in place.
- From Q1 2027, HLS will manage distribution, promotion and medical education, while Bayer retains regulatory and supply responsibilities. HLS will also record net sales and pay royalties to Bayer.
Takeaways:
The agreement expands HLS Therapeutics’ cardiovascular portfolio into heart failure, strengthening its presence in the Canadian pharmaceutical market. Taking over Verquvo ‘s commercialization provides HLS with access to an already authorized and reimbursed product, potentially accelerating market penetration while generating royalty-based returns for Bayer. The partnership also highlights the growing role of commercial licensing agreements in expanding pharmaceutical companies’ portfolios without requiring them to develop new therapies internally. HLS’s ability to drive adoption will depend on effective physician engagement and competition within the heart failure treatment market.
Source: CA Newswire
